Posted in Clinical Data Allogene stock sails after CAR T clears residual lymphoma in early data cut April 13, 2026 BioSpace Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning. Clinical DataOncologyRead full story